Zivo Bioscience, Inc. 8K

ZIVO Bioscience’s Board has decided to deregister its securities and cease SEC reporting to reduce costs and dilution while focusing resources on anticipated revenue growth from its AgTech and animal health businesses.

ZIVO Bioscience, Inc. announced via a special CEO letter that its Board of Directors has decided to deregister the company’s securities with the SEC and cease being a public reporting company, citing the disproportionate costs and shareholder dilution associated with maintaining a public listing relative to its early-stage revenue profile. The company expects that going non-reporting will allow it to redeploy capital from compliance and listing expenses into its operations, particularly as it anticipates meaningful near-term revenue and potentially its first positive cash flow from its AgTech product line through an established distribution partner. The letter also provides a business update noting ongoing due diligence by major animal health companies on its non-antibiotic immune-modulating technology, planned use of its product in avian influenza studies funded by the U.S. Department of Agriculture through the University of Georgia, commercial interest and capacity expansion for its ZIVO LIFE microalgae ingredient, and governance measures such as eliminating board compensation and CEO equity purchases at market prices to align with shareholders.

Filing Facts

CIK

1101026

Ticker

-

Form

8K

Source Type

sec

Accession

0001654954-26-002928

Alert Tier

8